- Company
- 15 domestic pharmaceuticals, focus on 'COVID-19' treatment
- by Nho, Byung Chul Mar 11, 2020 06:27am
- Domestic pharmaceutical bio companies and government agencies are concentrating on developing COVID-19 vaccines and treatments. In response to COVID-19, opinions are urged to strengthen government support and expand public-private cooperation in order to preemptively respond to similar infectious diseases. According to the KPBMA, 15 domes
- Policy
- Ibrance & Besivo were added to the price-volume agreement
- by Lee, Hye-Kyung Mar 10, 2020 01:43pm
- Ildong’s Besivo (Besifovir dipivoxil maleate) & Pfizer Korea’s Ibrance (Palbociclib)75mg/100mg/125mg were added to the price-volume agreement negotiation monitoring of the first quarter of this year. Novartis Korea's Entresto (Sacubitril/Valsartan Sod Hydrate) 50mg/100mg/200mg & Myung In Pharm's Q pam (Levitiracetam) 500mg are also bein
- Company
- Next-gen flu drug Xofluxa revs up for reimbursement listing
- by Eo, Yun-Ho Mar 10, 2020 06:29am
- Next-generation flu treatment Xofluza is now seeking for National Health Insurance reimbursement. Pharmaceutical industry sources reported, Roche Korea has submitted a reimbursement listing application for Xofluza (baloxavir). Finally approved after two-decade-long reign of Tamiflu (oseltamivir), Xofluza grabbed the industry’s atten
- Policy
- CSL Behring steps into hemophilia treatment market in Korea
- by Lee, Tak-Sun Mar 10, 2020 06:29am
- CSL Behring, a subsidiary of Australian-based global pharmaceutical company CSL, is to join the hemophilia treatment competition in Korea. The company acquired approval on hemophilia B treatment Idelbion injection on Mar. 5, after receiving a marketing license on Afstyla infection, a hemophilia A treatment developed based on SK Chemicals
- Policy
- Remdesivir, clinical trial at the SNUH
- by Lee, Tak-Sun Mar 10, 2020 06:29am
- Gilead's COVID-19 drug candidate, Remdesivir is conducting a clinical trial at Seoul National University Hospital. The trial is a multinational researcher-led clinical trial led by the National Institutes of Health (NIH) under the auspices of the World Health Organization. The MFDS approved Remdesivir’s multinational phase II clinical tri
- Policy
- ‘Korea Passing’ Xolair returns for second attempt on DREC
- by Lee, Hye-Kyung Mar 10, 2020 06:29am
- Although it abruptly dropped out from pricing negotiation in Korea for a better reimbursement listing in China, Novartis’ asthma treatment Xolair (omalizumab) has crossed the first threshold of reimbursement listing in Korea. Daehwa Pharmaceutical’s Liporaxel would proceed to negotiate pricing with National Health Insurance Service (NH
- Company
- How long do pharmaceuticals have to work from home?
- by Kim, Jin-Gu Mar 10, 2020 06:28am
- More domestic pharmaceutical companies have decided to work from home to prevent the spread of COVID-19. Following Dong-A ST and GC Pharm, Chong Kun Dang joined the ranks of all employees from home. Chong Kun Dang said five days ago that it will start working from home for all employees. it will be up to the 13th. Chong Kun Dang and its af
- Company
- Verzenio pricing negotiation to overlap with Ibrance
- by Eo, Yun-Ho Mar 9, 2020 08:00am
- After passing Ibrance, Health Insurance Review and Assessment Service (HIRA) continuously passed Verzenio. The newly passed drug would likely to overlap its pricing negotiation with Ibrance. Korean pharmaceutical industry source reported Lilly’s cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor Verzenio was given a green light for Nati
- Hospitals tighten their belts due to COVID-19
- by Lee. Ji hyun Mar 9, 2020 08:00am
- In the metropolitan area, Obstetrics and Gynecology Hospital A operates from 9 am to 1 pm as gynecological and internal outpatients dropped sharply due to prolonged COVID-19 crisis. The small and medium 200 beds hospital, in the Seoul metropolitan area, has withheld a contract for one of five pediatricians. As usual, the hospital would have
- Company
- Tylenol leads the pain relief market
- by Kim, Jin-Gu Mar 9, 2020 07:59am
- Tyreno made the most sales in the antipyretic analgesic market last year. Tylenol 8hrs ER performed poorly due to safety controversy, but overall brand sales increased slightly as Tylenol sold more. Geworin, the second-largest product, has grown significantly in the last five years. However, the sales gap between the 1st and 2nd places is
